| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 98 | 2024 | 1900 | 15.780 |
Why?
|
| Carcinoma, Neuroendocrine | 21 | 2024 | 743 | 8.250 |
Why?
|
| Hysterectomy | 49 | 2024 | 651 | 6.480 |
Why?
|
| Sentinel Lymph Node Biopsy | 28 | 2024 | 1451 | 4.240 |
Why?
|
| Genital Neoplasms, Female | 36 | 2024 | 788 | 3.480 |
Why?
|
| Laparoscopy | 33 | 2023 | 1301 | 3.240 |
Why?
|
| Lymph Nodes | 36 | 2024 | 3070 | 3.050 |
Why?
|
| Endometrial Neoplasms | 31 | 2024 | 1388 | 2.810 |
Why?
|
| Gynecologic Surgical Procedures | 25 | 2020 | 380 | 2.610 |
Why?
|
| Sentinel Lymph Node | 10 | 2024 | 229 | 2.250 |
Why?
|
| Ovarian Neoplasms | 24 | 2024 | 4785 | 2.100 |
Why?
|
| Minimally Invasive Surgical Procedures | 17 | 2024 | 509 | 2.040 |
Why?
|
| Indocyanine Green | 10 | 2024 | 125 | 2.000 |
Why?
|
| Cervix Uteri | 11 | 2023 | 247 | 1.970 |
Why?
|
| Neoplasm Staging | 65 | 2024 | 13994 | 1.860 |
Why?
|
| Trachelectomy | 6 | 2024 | 33 | 1.820 |
Why?
|
| Uterine Neoplasms | 8 | 2023 | 576 | 1.760 |
Why?
|
| Neuroendocrine Tumors | 5 | 2024 | 651 | 1.750 |
Why?
|
| Gynecology | 6 | 2021 | 235 | 1.740 |
Why?
|
| Lymphatic Metastasis | 36 | 2024 | 4956 | 1.740 |
Why?
|
| Carcinoma, Adenosquamous | 9 | 2020 | 107 | 1.730 |
Why?
|
| Vulvar Neoplasms | 10 | 2020 | 235 | 1.700 |
Why?
|
| Adenocarcinoma, Mucinous | 8 | 2023 | 440 | 1.690 |
Why?
|
| Female | 211 | 2024 | 148487 | 1.670 |
Why?
|
| Lymph Node Excision | 34 | 2024 | 2056 | 1.620 |
Why?
|
| Neoplasm Recurrence, Local | 30 | 2024 | 10382 | 1.550 |
Why?
|
| Carcinoma | 9 | 2023 | 2607 | 1.500 |
Why?
|
| Carcinoma, Squamous Cell | 24 | 2023 | 5585 | 1.430 |
Why?
|
| Frozen Sections | 3 | 2018 | 111 | 1.220 |
Why?
|
| Humans | 219 | 2024 | 270026 | 1.220 |
Why?
|
| Adult | 120 | 2024 | 81692 | 1.150 |
Why?
|
| Pelvis | 9 | 2018 | 383 | 1.110 |
Why?
|
| Adenocarcinoma | 26 | 2023 | 7883 | 1.100 |
Why?
|
| Retrospective Studies | 72 | 2024 | 39738 | 1.060 |
Why?
|
| Carcinoma, Small Cell | 2 | 2020 | 427 | 1.030 |
Why?
|
| Laparotomy | 4 | 2018 | 234 | 1.000 |
Why?
|
| Medical Oncology | 9 | 2022 | 1463 | 1.000 |
Why?
|
| Optical Imaging | 5 | 2020 | 158 | 0.970 |
Why?
|
| Cystadenoma, Mucinous | 3 | 2014 | 35 | 0.940 |
Why?
|
| Middle Aged | 109 | 2024 | 90031 | 0.940 |
Why?
|
| Vaginal Neoplasms | 4 | 2020 | 152 | 0.850 |
Why?
|
| Pelvic Exenteration | 8 | 2018 | 112 | 0.840 |
Why?
|
| Robotics | 15 | 2015 | 365 | 0.820 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2024 | 510 | 0.800 |
Why?
|
| Fellowships and Scholarships | 5 | 2015 | 410 | 0.800 |
Why?
|
| Carcinoid Tumor | 1 | 2024 | 278 | 0.790 |
Why?
|
| Pregnancy Outcome | 3 | 2019 | 682 | 0.760 |
Why?
|
| Aged | 86 | 2024 | 73128 | 0.750 |
Why?
|
| Quality of Life | 10 | 2020 | 4772 | 0.740 |
Why?
|
| Antiemetics | 2 | 2020 | 122 | 0.740 |
Why?
|
| Granisetron | 1 | 2020 | 8 | 0.720 |
Why?
|
| Carcinoma, Endometrioid | 6 | 2023 | 327 | 0.710 |
Why?
|
| Conization | 6 | 2021 | 38 | 0.710 |
Why?
|
| Ondansetron | 1 | 2020 | 39 | 0.710 |
Why?
|
| Counseling | 3 | 2020 | 381 | 0.700 |
Why?
|
| Disease-Free Survival | 22 | 2024 | 10258 | 0.700 |
Why?
|
| Algorithms | 7 | 2022 | 3897 | 0.690 |
Why?
|
| Rosaniline Dyes | 2 | 2018 | 109 | 0.670 |
Why?
|
| Coloring Agents | 7 | 2024 | 228 | 0.640 |
Why?
|
| Vomiting | 2 | 2020 | 362 | 0.640 |
Why?
|
| Nausea | 2 | 2020 | 540 | 0.630 |
Why?
|
| Young Adult | 38 | 2024 | 22134 | 0.620 |
Why?
|
| Registries | 5 | 2024 | 2205 | 0.610 |
Why?
|
| Pregnancy Complications, Neoplastic | 4 | 2020 | 235 | 0.590 |
Why?
|
| Pathology | 1 | 2018 | 97 | 0.570 |
Why?
|
| Uterine Hemorrhage | 2 | 2014 | 64 | 0.560 |
Why?
|
| Fertility | 2 | 2011 | 336 | 0.560 |
Why?
|
| Fertility Preservation | 5 | 2020 | 151 | 0.560 |
Why?
|
| Neoplasms, Second Primary | 2 | 2023 | 1387 | 0.550 |
Why?
|
| Fluorescent Dyes | 1 | 2018 | 468 | 0.530 |
Why?
|
| Neoplasm Grading | 9 | 2024 | 1821 | 0.520 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2020 | 512 | 0.510 |
Why?
|
| Aged, 80 and over | 42 | 2023 | 30923 | 0.490 |
Why?
|
| Gallbladder Neoplasms | 2 | 2009 | 244 | 0.490 |
Why?
|
| Robotic Surgical Procedures | 3 | 2019 | 532 | 0.480 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 999 | 0.480 |
Why?
|
| Positron-Emission Tomography | 5 | 2023 | 2196 | 0.470 |
Why?
|
| Hypesthesia | 1 | 2014 | 22 | 0.470 |
Why?
|
| Prognosis | 22 | 2024 | 22451 | 0.470 |
Why?
|
| Positron Emission Tomography Computed Tomography | 6 | 2023 | 880 | 0.460 |
Why?
|
| Obesity, Morbid | 2 | 2014 | 234 | 0.460 |
Why?
|
| Endometrial Hyperplasia | 1 | 2014 | 124 | 0.440 |
Why?
|
| DNA Copy Number Variations | 1 | 2020 | 1552 | 0.440 |
Why?
|
| Occupational Diseases | 1 | 2014 | 131 | 0.430 |
Why?
|
| Fluorodeoxyglucose F18 | 7 | 2023 | 1260 | 0.430 |
Why?
|
| Leiomyoma | 1 | 2014 | 161 | 0.430 |
Why?
|
| Survival Rate | 18 | 2024 | 12508 | 0.430 |
Why?
|
| Granulosa Cell Tumor | 2 | 2024 | 81 | 0.430 |
Why?
|
| Intraoperative Care | 2 | 2012 | 274 | 0.430 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3398 | 0.420 |
Why?
|
| Endometrium | 3 | 2019 | 460 | 0.420 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 16640 | 0.420 |
Why?
|
| Physicians | 1 | 2021 | 851 | 0.410 |
Why?
|
| Immunotherapy | 4 | 2020 | 3551 | 0.410 |
Why?
|
| Chemoradiotherapy | 4 | 2019 | 2027 | 0.410 |
Why?
|
| Scientific Misconduct | 1 | 2012 | 20 | 0.400 |
Why?
|
| Tomography, Emission-Computed | 1 | 2013 | 334 | 0.400 |
Why?
|
| Adaptation, Psychological | 3 | 2020 | 787 | 0.400 |
Why?
|
| Oncology Service, Hospital | 1 | 2012 | 49 | 0.400 |
Why?
|
| Melanoma | 7 | 2024 | 5594 | 0.400 |
Why?
|
| Aorta, Abdominal | 1 | 2012 | 150 | 0.390 |
Why?
|
| Hernia, Ventral | 1 | 2013 | 163 | 0.380 |
Why?
|
| Postoperative Complications | 13 | 2019 | 5666 | 0.380 |
Why?
|
| Predictive Value of Tests | 10 | 2019 | 4944 | 0.370 |
Why?
|
| Sexual Behavior | 3 | 2013 | 313 | 0.360 |
Why?
|
| Radiopharmaceuticals | 5 | 2023 | 1341 | 0.360 |
Why?
|
| Cross-Sectional Studies | 5 | 2024 | 4470 | 0.350 |
Why?
|
| Bevacizumab | 4 | 2022 | 958 | 0.350 |
Why?
|
| Social Media | 1 | 2013 | 208 | 0.330 |
Why?
|
| Blood Loss, Surgical | 7 | 2019 | 294 | 0.330 |
Why?
|
| Topotecan | 2 | 2022 | 248 | 0.330 |
Why?
|
| Radionuclide Imaging | 5 | 2008 | 654 | 0.330 |
Why?
|
| Genomics | 1 | 2020 | 2834 | 0.330 |
Why?
|
| Cisplatin | 4 | 2023 | 2496 | 0.330 |
Why?
|
| Uterus | 2 | 2016 | 798 | 0.330 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 340 | 0.320 |
Why?
|
| Surveys and Questionnaires | 9 | 2021 | 5906 | 0.310 |
Why?
|
| Treatment Outcome | 23 | 2023 | 33692 | 0.300 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2024 | 261 | 0.300 |
Why?
|
| Fatigue | 1 | 2014 | 1278 | 0.300 |
Why?
|
| Sensitivity and Specificity | 7 | 2023 | 5153 | 0.290 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 2 | 2019 | 107 | 0.290 |
Why?
|
| Standard of Care | 2 | 2023 | 275 | 0.280 |
Why?
|
| Surgical Oncology | 2 | 2020 | 211 | 0.280 |
Why?
|
| Length of Stay | 9 | 2019 | 2001 | 0.270 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 529 | 0.270 |
Why?
|
| Cohort Studies | 9 | 2024 | 9464 | 0.270 |
Why?
|
| Workload | 3 | 2018 | 194 | 0.260 |
Why?
|
| Preoperative Care | 6 | 2024 | 1552 | 0.260 |
Why?
|
| Pain | 1 | 2014 | 1697 | 0.260 |
Why?
|
| Survivors | 2 | 2015 | 1022 | 0.260 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 3 | 2019 | 339 | 0.260 |
Why?
|
| Antineoplastic Agents | 8 | 2020 | 14613 | 0.260 |
Why?
|
| Antineoplastic Agents, Hormonal | 3 | 2024 | 841 | 0.250 |
Why?
|
| Combined Modality Therapy | 6 | 2023 | 9039 | 0.250 |
Why?
|
| Neoplasms | 5 | 2021 | 15900 | 0.240 |
Why?
|
| Myometrium | 3 | 2015 | 82 | 0.240 |
Why?
|
| Sarcoma, Endometrial Stromal | 1 | 2024 | 20 | 0.240 |
Why?
|
| Follow-Up Studies | 16 | 2020 | 15172 | 0.240 |
Why?
|
| Mutation | 4 | 2024 | 15900 | 0.240 |
Why?
|
| Health Status | 3 | 2020 | 630 | 0.240 |
Why?
|
| Feasibility Studies | 7 | 2021 | 2358 | 0.230 |
Why?
|
| Conservative Treatment | 2 | 2021 | 65 | 0.230 |
Why?
|
| Paclitaxel | 3 | 2022 | 2101 | 0.230 |
Why?
|
| Infertility, Female | 1 | 2006 | 209 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 8 | 2018 | 4043 | 0.230 |
Why?
|
| Prospective Studies | 10 | 2021 | 13378 | 0.230 |
Why?
|
| Pregnancy | 9 | 2020 | 8107 | 0.230 |
Why?
|
| Testosterone | 1 | 2009 | 638 | 0.220 |
Why?
|
| Antineoplastic Agents, Immunological | 4 | 2020 | 1334 | 0.220 |
Why?
|
| Reproducibility of Results | 7 | 2019 | 6182 | 0.220 |
Why?
|
| Texas | 5 | 2019 | 6430 | 0.220 |
Why?
|
| Human papillomavirus 18 | 1 | 2023 | 42 | 0.220 |
Why?
|
| Clinical Competence | 6 | 2022 | 1323 | 0.220 |
Why?
|
| Mesonephroma | 1 | 2023 | 17 | 0.220 |
Why?
|
| Disease Progression | 5 | 2023 | 6840 | 0.220 |
Why?
|
| Technetium Tc 99m Sulfur Colloid | 2 | 2017 | 113 | 0.220 |
Why?
|
| Ovarian Cysts | 1 | 2023 | 41 | 0.220 |
Why?
|
| Paintings | 1 | 2002 | 5 | 0.220 |
Why?
|
| Medicine in the Arts | 1 | 2002 | 11 | 0.210 |
Why?
|
| Famous Persons | 1 | 2002 | 15 | 0.210 |
Why?
|
| Venous Thromboembolism | 3 | 2013 | 376 | 0.210 |
Why?
|
| Response Evaluation Criteria in Solid Tumors | 2 | 2020 | 164 | 0.210 |
Why?
|
| Retinoblastoma Binding Proteins | 1 | 2023 | 66 | 0.210 |
Why?
|
| Practice Patterns, Physicians' | 5 | 2015 | 1299 | 0.210 |
Why?
|
| Brain Neoplasms | 2 | 2016 | 4955 | 0.210 |
Why?
|
| Premenopause | 1 | 2023 | 138 | 0.210 |
Why?
|
| Patient Satisfaction | 2 | 2021 | 916 | 0.210 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2023 | 7779 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 6 | 2024 | 3993 | 0.210 |
Why?
|
| Carboplatin | 2 | 2023 | 879 | 0.210 |
Why?
|
| Sexual Dysfunction, Physiological | 1 | 2023 | 135 | 0.200 |
Why?
|
| Advance Directives | 2 | 2020 | 89 | 0.200 |
Why?
|
| Adenocarcinoma, Clear Cell | 4 | 2017 | 176 | 0.200 |
Why?
|
| Molecular Imaging | 1 | 2024 | 186 | 0.200 |
Why?
|
| Cancer Care Facilities | 2 | 2020 | 907 | 0.200 |
Why?
|
| Human papillomavirus 16 | 1 | 2023 | 255 | 0.190 |
Why?
|
| Blood Vessels | 2 | 2015 | 231 | 0.190 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2020 | 1400 | 0.190 |
Why?
|
| Risk Factors | 11 | 2020 | 17824 | 0.190 |
Why?
|
| Fluorescence | 2 | 2018 | 198 | 0.190 |
Why?
|
| Etoposide | 1 | 2023 | 905 | 0.190 |
Why?
|
| Existentialism | 1 | 2020 | 9 | 0.190 |
Why?
|
| Indazoles | 1 | 2023 | 310 | 0.190 |
Why?
|
| Ultrasonography | 2 | 2023 | 1928 | 0.180 |
Why?
|
| Organization and Administration | 1 | 2020 | 6 | 0.180 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2007 | 1577 | 0.180 |
Why?
|
| Civil Defense | 1 | 2020 | 13 | 0.180 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2020 | 46 | 0.180 |
Why?
|
| Chromogranins | 1 | 2020 | 86 | 0.180 |
Why?
|
| Baltimore | 1 | 2019 | 22 | 0.180 |
Why?
|
| Age Factors | 5 | 2018 | 5449 | 0.170 |
Why?
|
| Administration, Cutaneous | 1 | 2020 | 141 | 0.170 |
Why?
|
| Education, Medical, Graduate | 4 | 2022 | 700 | 0.170 |
Why?
|
| src-Family Kinases | 2 | 2013 | 487 | 0.170 |
Why?
|
| Advance Care Planning | 1 | 2020 | 93 | 0.170 |
Why?
|
| False Negative Reactions | 3 | 2019 | 284 | 0.170 |
Why?
|
| Intraoperative Complications | 2 | 2019 | 288 | 0.170 |
Why?
|
| Brachytherapy | 2 | 2023 | 1005 | 0.160 |
Why?
|
| Vagina | 2 | 2011 | 331 | 0.160 |
Why?
|
| Peritoneal Neoplasms | 3 | 2019 | 855 | 0.160 |
Why?
|
| Patient Selection | 3 | 2020 | 2026 | 0.160 |
Why?
|
| Fetal Viability | 1 | 2018 | 31 | 0.150 |
Why?
|
| Perineum | 1 | 2018 | 115 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2024 | 1469 | 0.150 |
Why?
|
| Adolescent | 14 | 2016 | 32646 | 0.150 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2023 | 874 | 0.150 |
Why?
|
| Electronic Health Records | 3 | 2020 | 847 | 0.150 |
Why?
|
| Canada | 1 | 2018 | 439 | 0.140 |
Why?
|
| Obesity | 2 | 2012 | 2901 | 0.140 |
Why?
|
| Molecular Targeted Therapy | 4 | 2024 | 2390 | 0.140 |
Why?
|
| Perception | 1 | 2019 | 349 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2020 | 503 | 0.140 |
Why?
|
| Lymphadenopathy | 1 | 2018 | 94 | 0.140 |
Why?
|
| Rare Diseases | 1 | 2020 | 358 | 0.140 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2024 | 2269 | 0.140 |
Why?
|
| Mental Health | 1 | 2020 | 412 | 0.140 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2015 | 517 | 0.140 |
Why?
|
| Fallopian Tubes | 2 | 2009 | 128 | 0.140 |
Why?
|
| Uterine Artery | 1 | 2016 | 31 | 0.130 |
Why?
|
| Platinum | 1 | 2016 | 142 | 0.130 |
Why?
|
| Lymphatic Vessels | 2 | 2015 | 138 | 0.130 |
Why?
|
| Data Collection | 3 | 2009 | 608 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 530 | 0.130 |
Why?
|
| Carcinosarcoma | 1 | 2017 | 146 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2020 | 3653 | 0.130 |
Why?
|
| Papanicolaou Test | 1 | 2016 | 116 | 0.130 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 624 | 0.130 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 698 | 0.130 |
Why?
|
| Invertebrate Hormones | 1 | 1995 | 5 | 0.120 |
Why?
|
| Aplysia | 1 | 1995 | 22 | 0.120 |
Why?
|
| Ovariectomy | 3 | 2013 | 369 | 0.120 |
Why?
|
| Time Factors | 5 | 2020 | 12953 | 0.120 |
Why?
|
| Mind-Body Therapies | 1 | 2014 | 29 | 0.120 |
Why?
|
| Neurosecretory Systems | 1 | 1995 | 65 | 0.120 |
Why?
|
| Body Mass Index | 5 | 2019 | 2238 | 0.120 |
Why?
|
| Hospitals | 1 | 2018 | 482 | 0.120 |
Why?
|
| Academic Medical Centers | 1 | 2018 | 681 | 0.120 |
Why?
|
| Cranial Irradiation | 1 | 2016 | 322 | 0.120 |
Why?
|
| Intraoperative Period | 2 | 2004 | 250 | 0.120 |
Why?
|
| Risk Adjustment | 1 | 2014 | 74 | 0.120 |
Why?
|
| Myxoma | 1 | 2014 | 66 | 0.110 |
Why?
|
| Consensus | 3 | 2024 | 1100 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2024 | 9035 | 0.110 |
Why?
|
| Remission Induction | 1 | 2020 | 3648 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2013 | 65 | 0.110 |
Why?
|
| Pelvic Neoplasms | 1 | 2015 | 199 | 0.110 |
Why?
|
| Spirituality | 1 | 2014 | 129 | 0.110 |
Why?
|
| Risk | 2 | 2014 | 1937 | 0.110 |
Why?
|
| Urogenital Neoplasms | 1 | 2014 | 115 | 0.110 |
Why?
|
| Odds Ratio | 1 | 2018 | 2296 | 0.110 |
Why?
|
| Decision Making | 2 | 2020 | 1249 | 0.110 |
Why?
|
| Urinary Reservoirs, Continent | 1 | 2013 | 39 | 0.110 |
Why?
|
| Medical Records | 1 | 2014 | 442 | 0.110 |
Why?
|
| Acetamides | 1 | 2013 | 111 | 0.110 |
Why?
|
| RNA-Binding Proteins | 1 | 2018 | 1017 | 0.100 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2013 | 67 | 0.100 |
Why?
|
| Cancer Survivors | 1 | 2020 | 744 | 0.100 |
Why?
|
| Urinary Diversion | 1 | 2013 | 86 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2018 | 2417 | 0.100 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 62 | 0.100 |
Why?
|
| Venous Thrombosis | 2 | 2013 | 381 | 0.100 |
Why?
|
| Hospitals, Community | 1 | 2012 | 76 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 2 | 2020 | 2388 | 0.100 |
Why?
|
| Hospitals, University | 1 | 2012 | 218 | 0.100 |
Why?
|
| Surgeons | 1 | 2018 | 489 | 0.100 |
Why?
|
| Disease Management | 2 | 2015 | 1087 | 0.100 |
Why?
|
| Genital Diseases, Female | 1 | 2012 | 60 | 0.100 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2015 | 742 | 0.100 |
Why?
|
| Patient Preference | 1 | 2014 | 228 | 0.100 |
Why?
|
| Genes, p53 | 1 | 2016 | 1140 | 0.100 |
Why?
|
| Blood Transfusion | 4 | 2019 | 581 | 0.100 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2018 | 6253 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2013 | 478 | 0.090 |
Why?
|
| Research Report | 1 | 2012 | 136 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2022 | 7892 | 0.090 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 1388 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2022 | 1442 | 0.090 |
Why?
|
| Diagnostic Imaging | 1 | 2018 | 1174 | 0.090 |
Why?
|
| Biomarkers, Tumor | 4 | 2024 | 10694 | 0.090 |
Why?
|
| Hysterectomy, Vaginal | 1 | 2010 | 35 | 0.090 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2012 | 209 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2024 | 5432 | 0.090 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 4820 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2357 | 0.090 |
Why?
|
| Aorta | 2 | 2010 | 665 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2010 | 125 | 0.090 |
Why?
|
| Salpingo-oophorectomy | 2 | 2020 | 49 | 0.080 |
Why?
|
| Anxiety | 2 | 2014 | 1236 | 0.080 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2016 | 1707 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2013 | 488 | 0.080 |
Why?
|
| Analgesics | 1 | 2012 | 409 | 0.080 |
Why?
|
| Pelvic Bones | 1 | 2010 | 102 | 0.080 |
Why?
|
| United States | 4 | 2020 | 15776 | 0.080 |
Why?
|
| Patient Participation | 2 | 2019 | 453 | 0.080 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2010 | 199 | 0.080 |
Why?
|
| Operative Time | 2 | 2020 | 251 | 0.080 |
Why?
|
| Calcium | 1 | 1995 | 1540 | 0.080 |
Why?
|
| Colpotomy | 1 | 2008 | 8 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 3 | 2024 | 496 | 0.080 |
Why?
|
| Quality of Health Care | 1 | 2013 | 616 | 0.080 |
Why?
|
| Cholecystectomy | 1 | 2009 | 118 | 0.080 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2009 | 334 | 0.080 |
Why?
|
| Doxorubicin | 1 | 2015 | 3142 | 0.080 |
Why?
|
| CA-125 Antigen | 1 | 2009 | 228 | 0.070 |
Why?
|
| Carcinoma, Papillary | 2 | 2015 | 566 | 0.070 |
Why?
|
| Laparoscopes | 1 | 2006 | 11 | 0.070 |
Why?
|
| Thiazoles | 1 | 2011 | 723 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2018 | 5403 | 0.070 |
Why?
|
| Outpatients | 2 | 2020 | 460 | 0.070 |
Why?
|
| Technetium Compounds | 1 | 2006 | 12 | 0.070 |
Why?
|
| Fractures, Bone | 1 | 2010 | 310 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2009 | 822 | 0.070 |
Why?
|
| Patient Safety | 1 | 2012 | 612 | 0.070 |
Why?
|
| Pyridines | 1 | 2013 | 1310 | 0.070 |
Why?
|
| Abdominal Pain | 1 | 2009 | 378 | 0.070 |
Why?
|
| Lung Diseases | 1 | 2012 | 751 | 0.070 |
Why?
|
| Megestrol Acetate | 1 | 2006 | 30 | 0.070 |
Why?
|
| Neoplasm, Residual | 3 | 2024 | 1742 | 0.070 |
Why?
|
| Hemostasis, Surgical | 1 | 2006 | 55 | 0.070 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2006 | 49 | 0.070 |
Why?
|
| Artifacts | 1 | 2009 | 536 | 0.070 |
Why?
|
| Electrocoagulation | 1 | 2006 | 67 | 0.070 |
Why?
|
| Research Design | 1 | 2013 | 1569 | 0.070 |
Why?
|
| Pancreatic Neoplasms | 1 | 2023 | 5250 | 0.060 |
Why?
|
| Surgical Flaps | 1 | 2011 | 884 | 0.060 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2007 | 361 | 0.060 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2014 | 1265 | 0.060 |
Why?
|
| Pyrimidines | 2 | 2021 | 3662 | 0.060 |
Why?
|
| Carcinoma, Large Cell | 1 | 2024 | 98 | 0.060 |
Why?
|
| Ligands | 1 | 2007 | 1014 | 0.060 |
Why?
|
| Cell Survival | 3 | 2018 | 3055 | 0.060 |
Why?
|
| Decision Trees | 1 | 2004 | 181 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2024 | 2031 | 0.060 |
Why?
|
| Hot Flashes | 1 | 2023 | 35 | 0.060 |
Why?
|
| New York | 1 | 2023 | 102 | 0.060 |
Why?
|
| Age of Onset | 1 | 2006 | 852 | 0.060 |
Why?
|
| Deoxycytidine | 1 | 2009 | 1389 | 0.050 |
Why?
|
| Male | 11 | 2021 | 127915 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 2014 | 3842 | 0.050 |
Why?
|
| Papillomavirus Vaccines | 1 | 2006 | 197 | 0.050 |
Why?
|
| Philadelphia | 1 | 2002 | 36 | 0.050 |
Why?
|
| Viral Vaccines | 1 | 2006 | 359 | 0.050 |
Why?
|
| Leuprolide | 1 | 2023 | 66 | 0.050 |
Why?
|
| Reproduction | 1 | 2005 | 278 | 0.050 |
Why?
|
| Radiography | 2 | 2022 | 1984 | 0.050 |
Why?
|
| Mucous Membrane | 1 | 2023 | 260 | 0.050 |
Why?
|
| Smoking | 1 | 2012 | 2548 | 0.050 |
Why?
|
| North America | 1 | 2023 | 337 | 0.050 |
Why?
|
| Papillomaviridae | 1 | 2006 | 636 | 0.050 |
Why?
|
| Cell Line, Tumor | 4 | 2024 | 14824 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2010 | 1857 | 0.050 |
Why?
|
| History, 19th Century | 1 | 2002 | 142 | 0.050 |
Why?
|
| Radiation Injuries | 1 | 2010 | 1469 | 0.050 |
Why?
|
| Social Support | 1 | 2005 | 590 | 0.050 |
Why?
|
| Comorbidity | 1 | 2008 | 2389 | 0.050 |
Why?
|
| Cystoscopy | 1 | 2022 | 92 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2024 | 12019 | 0.050 |
Why?
|
| Colon | 1 | 2005 | 653 | 0.050 |
Why?
|
| Accreditation | 1 | 2022 | 136 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2016 | 2316 | 0.050 |
Why?
|
| B7-H1 Antigen | 2 | 2020 | 1081 | 0.050 |
Why?
|
| Electrosurgery | 2 | 2013 | 29 | 0.050 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2006 | 599 | 0.050 |
Why?
|
| Pandemics | 2 | 2020 | 1603 | 0.050 |
Why?
|
| Logistic Models | 3 | 2012 | 3438 | 0.040 |
Why?
|
| Organizational Innovation | 1 | 2020 | 62 | 0.040 |
Why?
|
| Conversion to Open Surgery | 1 | 2019 | 8 | 0.040 |
Why?
|
| Mesothelioma | 1 | 2005 | 558 | 0.040 |
Why?
|
| Child | 5 | 2012 | 30466 | 0.040 |
Why?
|
| Endometriosis | 1 | 2023 | 231 | 0.040 |
Why?
|
| Coronavirus | 1 | 2020 | 37 | 0.040 |
Why?
|
| Neovascularization, Pathologic | 1 | 2007 | 1581 | 0.040 |
Why?
|
| Organoplatinum Compounds | 2 | 2013 | 704 | 0.040 |
Why?
|
| Japan | 1 | 2020 | 235 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 144 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2021 | 274 | 0.040 |
Why?
|
| Hospital Charges | 1 | 2020 | 87 | 0.040 |
Why?
|
| General Surgery | 1 | 2002 | 331 | 0.040 |
Why?
|
| Phthalazines | 1 | 2021 | 262 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2019 | 5099 | 0.040 |
Why?
|
| Spectroscopy, Near-Infrared | 1 | 2020 | 173 | 0.040 |
Why?
|
| Monitoring, Intraoperative | 1 | 2020 | 264 | 0.040 |
Why?
|
| Oocyte Donation | 1 | 1998 | 40 | 0.040 |
Why?
|
| Interdisciplinary Communication | 1 | 2020 | 271 | 0.040 |
Why?
|
| Internationality | 1 | 2019 | 205 | 0.040 |
Why?
|
| Infection Control | 1 | 2020 | 276 | 0.040 |
Why?
|
| Capecitabine | 1 | 2019 | 390 | 0.040 |
Why?
|
| Neoplasm Metastasis | 3 | 2017 | 5309 | 0.040 |
Why?
|
| Groin | 1 | 2018 | 78 | 0.040 |
Why?
|
| Documentation | 1 | 2019 | 213 | 0.040 |
Why?
|
| Ribonuclease III | 1 | 2018 | 182 | 0.040 |
Why?
|
| Pyrroles | 1 | 2021 | 587 | 0.040 |
Why?
|
| Color | 1 | 2017 | 73 | 0.040 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2018 | 256 | 0.030 |
Why?
|
| Mice | 4 | 2024 | 35461 | 0.030 |
Why?
|
| Tissue Fixation | 1 | 2017 | 136 | 0.030 |
Why?
|
| Formaldehyde | 1 | 2017 | 115 | 0.030 |
Why?
|
| Abdomen | 1 | 2018 | 349 | 0.030 |
Why?
|
| Paraffin Embedding | 1 | 2017 | 221 | 0.030 |
Why?
|
| Mitotic Index | 1 | 2016 | 162 | 0.030 |
Why?
|
| Survival Analysis | 2 | 2020 | 9288 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 4318 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2005 | 6204 | 0.030 |
Why?
|
| Fluorescein Angiography | 1 | 2016 | 148 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.030 |
Why?
|
| Animals | 5 | 2024 | 61707 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2012 | 16986 | 0.030 |
Why?
|
| Egtazic Acid | 1 | 1995 | 53 | 0.030 |
Why?
|
| Seawater | 1 | 1995 | 16 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2023 | 1716 | 0.030 |
Why?
|
| Mice, Nude | 2 | 2013 | 4329 | 0.030 |
Why?
|
| Betacoronavirus | 1 | 2020 | 513 | 0.030 |
Why?
|
| Patient Care Team | 1 | 2020 | 822 | 0.030 |
Why?
|
| Extracellular Space | 1 | 1995 | 145 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2018 | 678 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2016 | 366 | 0.030 |
Why?
|
| Electrophysiology | 1 | 1995 | 360 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 4462 | 0.030 |
Why?
|
| Chorionic Gonadotropin | 1 | 1994 | 127 | 0.030 |
Why?
|
| Biopsy | 2 | 2012 | 3384 | 0.030 |
Why?
|
| Tissue Donors | 1 | 1998 | 812 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 3911 | 0.030 |
Why?
|
| Electric Stimulation | 1 | 1995 | 490 | 0.030 |
Why?
|
| Fallopian Tube Neoplasms | 1 | 2014 | 154 | 0.030 |
Why?
|
| Amniotic Fluid | 1 | 1994 | 154 | 0.030 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2013 | 285 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 854 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 452 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2013 | 232 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2011 | 2472 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2018 | 2196 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2145 | 0.030 |
Why?
|
| Psychotherapy | 1 | 2014 | 249 | 0.030 |
Why?
|
| Microtubules | 1 | 2013 | 326 | 0.030 |
Why?
|
| Colombia | 1 | 2012 | 61 | 0.030 |
Why?
|
| Urinary Incontinence | 1 | 2013 | 148 | 0.020 |
Why?
|
| Pulmonary Atelectasis | 1 | 2012 | 51 | 0.020 |
Why?
|
| Blood Volume | 1 | 2012 | 106 | 0.020 |
Why?
|
| Morpholines | 1 | 2013 | 296 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2017 | 1017 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2646 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2023 | 3437 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 651 | 0.020 |
Why?
|
| Perioperative Period | 1 | 2012 | 149 | 0.020 |
Why?
|
| Diagnostic Techniques, Obstetrical and Gynecological | 1 | 2010 | 7 | 0.020 |
Why?
|
| Cryosurgery | 1 | 2013 | 196 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 322 | 0.020 |
Why?
|
| Pubic Bone | 1 | 2010 | 16 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2013 | 1359 | 0.020 |
Why?
|
| Statistics, Nonparametric | 1 | 2012 | 982 | 0.020 |
Why?
|
| Pain Measurement | 1 | 2014 | 1017 | 0.020 |
Why?
|
| Acetabulum | 1 | 2010 | 41 | 0.020 |
Why?
|
| Incidence | 2 | 2010 | 5806 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2018 | 3999 | 0.020 |
Why?
|
| Metastasectomy | 1 | 2011 | 209 | 0.020 |
Why?
|
| Developing Countries | 1 | 2012 | 340 | 0.020 |
Why?
|
| Pilot Projects | 2 | 2006 | 2843 | 0.020 |
Why?
|
| Sacrum | 1 | 2010 | 138 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2018 | 2616 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 1248 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 1994 | 1305 | 0.020 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2018 | 1840 | 0.020 |
Why?
|
| Immunohistochemistry | 2 | 2010 | 7632 | 0.020 |
Why?
|
| Overweight | 1 | 2012 | 484 | 0.020 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1011 | 0.020 |
Why?
|
| Apoptosis | 2 | 2013 | 7740 | 0.020 |
Why?
|
| Graft Survival | 1 | 2011 | 1079 | 0.020 |
Why?
|
| Health Care Costs | 1 | 2013 | 698 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2013 | 2136 | 0.020 |
Why?
|
| Dasatinib | 1 | 2011 | 881 | 0.020 |
Why?
|
| Endoscopy | 1 | 2010 | 489 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2015 | 5062 | 0.020 |
Why?
|
| Pulmonary Embolism | 1 | 2010 | 341 | 0.020 |
Why?
|
| Bone Density | 1 | 2010 | 467 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2014 | 1713 | 0.020 |
Why?
|
| Retroperitoneal Space | 1 | 2006 | 156 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2016 | 2161 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2011 | 3585 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2018 | 2883 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2006 | 286 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2015 | 4360 | 0.020 |
Why?
|
| Depression | 1 | 2014 | 1731 | 0.010 |
Why?
|
| Progestins | 1 | 2004 | 92 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 2008 | 965 | 0.010 |
Why?
|
| Early Detection of Cancer | 1 | 2011 | 1338 | 0.010 |
Why?
|
| Mothers | 1 | 2006 | 416 | 0.010 |
Why?
|
| Prevalence | 1 | 2010 | 3353 | 0.010 |
Why?
|
| SEER Program | 1 | 2006 | 1047 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7230 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2018 | 12083 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 3599 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2010 | 6752 | 0.010 |
Why?
|
| Reimbursement Mechanisms | 1 | 1998 | 76 | 0.010 |
Why?
|
| Physical Examination | 1 | 1998 | 304 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 4958 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2005 | 6367 | 0.010 |
Why?
|
| Thiocyanates | 1 | 1994 | 16 | 0.010 |
Why?
|
| Chromatography, Gel | 1 | 1994 | 160 | 0.010 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 1994 | 56 | 0.010 |
Why?
|
| Radioimmunoassay | 1 | 1994 | 203 | 0.010 |
Why?
|
| Amniocentesis | 1 | 1994 | 83 | 0.010 |
Why?
|
| Pregnancy Trimester, Second | 1 | 1994 | 168 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2005 | 5137 | 0.010 |
Why?
|
| Mental Disorders | 1 | 1998 | 881 | 0.010 |
Why?
|
| Genetic Testing | 1 | 1998 | 1696 | 0.010 |
Why?
|
| Protein Binding | 1 | 1994 | 3477 | 0.000 |
Why?
|